Home >AIM and small-cap hubInsight and IdeasOverviewFree updatesQuick start fundsii Super 60Model PortfoliosWinter Portfolios2020/21 outlookQuarterly reviewTrading tips and ideasAIM and small-cap hubInsider videosii PodcastsHistorical recommendationsMeet the expertsAIM and small-cap hub Get the lowdown on smaller company shares and all that matters on the junior market. 20 NovemberRichard Beddard: how to score this rapidly evolving AIM firm?The company has been making products for 100 years, but judging profit is tricky.by Richard Beddard11 NovemberEagle Eye rockets, and other AIM shares followBlue-chip shares have raced higher, and now these AIM stocks are playing catch up.by Graeme Evans6 NovemberAIM stocks to own in the second lockdownHealthcare, construction, property, music and DIY companies stand to benefit from enforced isolation.by Andrew Hore29 OctoberCovid-19 tester makes AIM debutSourceBio International is valued at £120 million and joins booming Novacyt and Avacta.by Graeme Evans29 OctoberNovacyt shares: an insider’s view on 21,000% price surgeAn analyst debates whether the current price is justified, what Novacyt could be worth one day and more.by Lee Wild26 OctoberInsider: almost £1m spent on shares in this well-known AIM pairBoth companies have grabbed headlines this year. Now bosses are buying and the share prices are rising.by Graeme EvansRegister to receive free daily market commentary, insight and analysis from our award-winning editorial team.
20 NovemberRichard Beddard: how to score this rapidly evolving AIM firm?The company has been making products for 100 years, but judging profit is tricky.by Richard Beddard
11 NovemberEagle Eye rockets, and other AIM shares followBlue-chip shares have raced higher, and now these AIM stocks are playing catch up.by Graeme Evans
6 NovemberAIM stocks to own in the second lockdownHealthcare, construction, property, music and DIY companies stand to benefit from enforced isolation.by Andrew Hore
29 OctoberCovid-19 tester makes AIM debutSourceBio International is valued at £120 million and joins booming Novacyt and Avacta.by Graeme Evans
29 OctoberNovacyt shares: an insider’s view on 21,000% price surgeAn analyst debates whether the current price is justified, what Novacyt could be worth one day and more.by Lee Wild
26 OctoberInsider: almost £1m spent on shares in this well-known AIM pairBoth companies have grabbed headlines this year. Now bosses are buying and the share prices are rising.by Graeme Evans